Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of chlorite to treat red blood cell diseases and indications mediated thereby

A chlorite, diabetes technology, applied in extracellular fluid diseases, metabolic diseases, blood diseases, etc., can solve problems such as no evidence of inhibition of AGE end-organ damage

Pending Publication Date: 2018-06-08
OXO TRANSLATIONAL SCI GMBH
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Newer non-insulin drugs as an add-on to metformin etc. can reduce HbA1c by 0.5-1%, but there is no evidence of inhibition of AGE production or reduction of actual end-organ damage and cannot be based on currently known science way to do this

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of chlorite to treat red blood cell diseases and indications mediated thereby
  • Use of chlorite to treat red blood cell diseases and indications mediated thereby
  • Use of chlorite to treat red blood cell diseases and indications mediated thereby

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0080] A preferred composition is WF10, eg, disclosed in US Patent No. 8,252,343 as an agent for the treatment of allergies, asthma and dermatitis.

[0081] WF10 is a sterile, pyrogen-free, 10% (w / v) dilute aqueous solution of the drug OXO-K993, which is analytically characterized as containing ionic chlorite (4.25%), chloride (2.0%), chlorate (1.5%), sulfate (0.7%) and sodium (4.0%) solution. Human clinical research has generated a large amount of safety evidence. When WF10 is infused at a daily dose of 0.5mL / kg for 5 consecutive days, followed by a 16-day drug-free interval, it constitutes a "cycle". In both regimens, patients received 6 cycles of treatment, and in another trial, patients received 4 cycles followed by maintenance every 6 weeks for up to 128 weeks. In any event, WF10 showed an excellent safety profile, with no steroid-like side effects, no immunosuppression, no antihistamine-like side effects, and no cardiovascular side effects.

[0082] WF10 has been shown...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides methods of treating hyperglycemia induced Red Blood Cell Disease / Dysfunction (RBCD) caused by generation of early and late glycation end products. The invention provides a method of treating hemolytic anemia, smoldering hemolytic anemia, sickle cell anemia, hemorrhagic diseases, hemorrhagic stroke, hemorrhagic bleeding. Method of treating RBCD to prevent progression to diabetes associated vascular complications is referred to as Syndrome X, particularly to prevent progression to chronic kidney disease, coronary vascular disease, and peripheral vascular disease.

Description

technical field [0001] The present invention relates to the treatment of hyperglycemia-induced red blood cell disease / dysfunction (RBCD) caused by the production of early and advanced glycation end products (AGE) and the indications associated with RBCD and related pathologies / disorders mediated by it Indication method. RBCD includes hemolytic anemia, smoldering hemolytic anemia, bleeding disorders, bleeding events, hemorrhagic bleeding. [0002] The present invention can treat RBCD caused by early glycation. RBCD in diabetes is biochemically quantified by the production of early glycation product HbA1c and is characterized morphologically by loss of discoid shape and deformability of RBCs. [0003] More specifically, the present invention relates to the use or use of chlorite solutions such as WF10 for such treatments. Background technique [0004] Red blood cells (RBCs), or erythrocytes, are the most common type of blood cell and are the vertebrate body's primary means ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K33/00A61P3/10
CPCA61K33/00A61K33/14A61P7/06A61P3/10A61K33/20
Inventor 派汶·马拉普雷萨万弗里德里克-威廉·屈内
Owner OXO TRANSLATIONAL SCI GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com